Evaluation of a methylation classifier for predicting pre-cancer lesion among women with abnormal results between HPV16/18 and cytology

Table 4 The follow-up data of women with histology < (His)HSIL+ according S5 scoring

	S5 scoring < 2.85	S5 scoring ≥ 2.85
HPV16/18 + (n)	68	24
HPV16/18 − (1 year later) (n)	40	1
Regression rate (%)	58.8	4.6
Cytology≥(TCT)HSIL+ (n)	60	16
Cytology<(TCT)HSIL+(1 year later) (n)	42	2
Regression rate (%)	71.7	12.5

As the descripted in the title of Table 4, “histology < (His)HSIL+” was diagnosed based on the colposcopy (until 2018 November). One year later (in 2019 November), we followed up women who were diagnosed as “histology < (His)HSIL+.” As these women were referred to colposcopy for HPV16/18+ or cytology ≥ (TCT)HSIL+, we analyzed the HPV16/18 genotyping and cytology in 2019 November, and we define the “regression” as cytology or HPV16/18 becoming negative 1 year later.
(His)HSIL+ histological high-grade squamous intraepithelial lesion or worse, (TCT)HSIL+ cytological high-grade squamous intraepithelial lesion or worse.

ISSN: 1868-7083